Lakefront Biotherapeutics NV (LKFT) intrinsic value & 10-year financials
Lakefront Biotherapeutics NV (LKFT) has a Graham intrinsic value of €161.76 per share. Over the last 10 fiscal years revenue grew 27.0% a year to €1.1B, with an average return on invested capital of -2.1%.
- Graham intrinsic value
- €161.76
- Revenue (FY2025)
- €1.1B
- Revenue growth (10-yr CAGR)
- 27.0%
- ROIC (10-yr avg)
- -2.1%
- Free cash flow (FY2025)
- -€271.2M
LKFT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | €1.1B | €320.9M | €4.87 | -€271.2M | 26.5% | 9.6% |
| FY2024 | €275.6M | €74.1M | €1.12 | -€336.7M | -68.3% | -6.6% |
| FY2023 | €239.7M | €211.7M | €3.21 | -€424.7M | -36.8% | -3.2% |
| FY2022 | €505.3M | -€218.0M | -€3.32 | -€527.9M | -52.9% | -10.4% |
| FY2021 | €484.8M | -€103.2M | -€1.58 | -€558.0M | -34.2% | -6.2% |
| FY2020 | €478.1M | -€305.4M | -€0.00 | -€469.9M | -37.4% | -6.4% |
| FY2019 | €845.0M | €149.8M | €0.00 | €3.2B | 43.8% | 18.1% |
| FY2018 | €288.8M | -€29.3M | -€0.00 | -€152.9M | -15.5% | -4.0% |
| FY2017 | €127.1M | -€115.7M | -€0.00 | -€152.3M | -70.7% | -10.1% |
| FY2016 | €129.5M | €54.0M | €0.00 | €234.9M | -8.9% | -1.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in EUR.
Executive summary
Lakefront Biotherapeutics NV is a consistent compounder, expanding top-line revenue at 27.0% annually over the past decade.
Lakefront Biotherapeutics NV 10-year average ROIC is N/A; capital efficiency cannot be assessed from the available history.
Over the decade, Lakefront Biotherapeutics NV shows that management has aggressively returned capital to shareholders by retiring 99.9% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Lakefront Biotherapeutics NV is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $161.76 per share.